A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia
about
Early interventions in risk groups for schizophrenia: what are we waiting for?Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signalingThe impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaKetamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model.Glutamate-mediated excitotoxicity in schizophrenia: a review.Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder.Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial.Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog.Glutamate and dopamine in schizophrenia: an update for the 21st centuryEffects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.Drug repurposing and emerging adjunctive treatments for schizophrenia.Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.Recent developments in the behavioural and pharmacological enhancement of extinction of drug seeking.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.D-serine, a novel uremic toxin, induces senescence in human renal tubular cells via GCN2 activation.Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.Oral administration of D-alanine in monkeys robustly increases plasma and cerebrospinal fluid levels but experimental D-amino acid oxidase inhibitors had minimal effect.Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.Natural Medicines for Psychotic Disorders: A Systematic Review.Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.d-Serine administration affects nitric oxide synthase 1 adaptor protein and DISC1 expression in sex-specific manner.Neurophysiological Effects of Bitopertin in SchizophreniaEfficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysisD-Serine in Neuropsychiatric Disorders: New Advances
P2860
Q26747545-0C4F89DD-DC37-4908-822B-684664EC3DDEQ27023967-7B45E3AD-901A-415F-A921-1678CF27BB37Q28081110-5306355A-6C45-4C13-9098-3EF04B033492Q30714646-B9C10B02-C86B-4498-9B6A-6D507CD14C4AQ30845062-D4D52D4B-AEEE-489B-8DAB-506CFD239344Q33842716-9D7B3CD4-6135-4B74-BE5C-D6903AD86274Q34458090-25C63B6C-E526-47A7-8D10-B614FB0318EAQ34661125-D898E8F8-64B3-4675-AC44-A85783A179FDQ35802177-19F4AEC7-9F56-45E4-AB8D-D2CA8A6A10C4Q36279413-47CAEEE7-2FD1-4953-B0D4-8C3D035F35CEQ36642660-65871039-FDEB-442B-87D2-ED49E3AC5948Q36799037-F14C3139-18D6-4FFA-ACC7-09EB4D57B85EQ36992322-038BD096-AE7E-427D-B581-F5007D35A544Q37662441-941B562F-50BC-443E-A9F5-D47DC33E5B3DQ38187948-1B48F5CF-E498-4343-906B-9CEC0792DA52Q38268878-A7A501C4-5590-4600-8FC4-32D73ACA8DDFQ38417631-EB31A742-9F4A-4CF8-B4A2-407697196CB8Q38669576-7820CFEA-95EA-4DE9-9698-6C3BAD697CD8Q38674558-79614513-F366-4E9F-95F5-8C45DECD3E72Q38699013-5919C0B2-BCF1-452B-83B3-D95C54B8973AQ38750121-6663FD3F-9357-4057-914B-17DA42379C7CQ41331053-58651F2A-649B-4174-BE8F-F1CCEB8E1536Q44487146-5E072D86-2F6F-4568-8883-977AAF7C906EQ46534256-379B65A5-29A0-4330-B04A-21CF068CDC8AQ48345910-850043F5-EDB8-4C9F-9A0D-40813869B293Q49363880-A1979D68-DCBF-4CEE-A175-15DFD1DB020BQ50750840-80FE42A8-9807-45FB-8DC5-B12A630B0039Q51730519-755EA4A6-2256-45F4-8588-F8F969481FA6Q57828993-7B2F018B-A1EE-47E9-9DF6-CC7C81D4113CQ58561523-580F7D7F-B2AA-4E54-AD1F-17D50DFADF98Q59052088-6C089F8E-E6E0-47BD-A138-05CBDFCE5B44
P2860
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@ast
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@en
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@nl
type
label
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@ast
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@en
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@nl
prefLabel
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@ast
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@en
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@nl
P2093
P356
P1476
A multicenter, add-on randomiz ...... tive symptoms of schizophrenia
@en
P2093
Adiel Doron
Alexander Teitelbaum
Ari A Gershon
Daniela Amital
David Liba
Mark Weiser
Michael Davidson
Mordechai Mashiach
Nomi Werbeloff
Shai Konas
P304
P356
10.4088/JCP.11M07031
P407
P577
2012-06-01T00:00:00Z